5 unknown, 1 completed, 1 withdrawn. 7 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Unknown 5, Completed 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 1, Unknown 1, Withdrawn 1 |
Follow Relapse: new trials by email Literature Review of Relapse trials Research Report on Relapse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Primaquine Double Dose for Radical Cure of Plasmodium Vivax in Colombia Primaquine double dose over 14 days, Primaquine single dose over 14 days - Malaria, Vivax, Relapse | Phase 2 / Phase 3 | Withdrawn | University of California, San Francisco | 2023-01-20 | 2023-05-11 | |
| Outcomes of Patients After Allo-HSCT With Decitabine and NAC decitabine, Acetylcysteine, Semustine - Engraft Failure, Relapse | Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 100 | 2021-07-01 | 2021-06-30 |
| Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute Leukemia Sorafenib - Acute Leukemia, Relapse | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 346 | 2020-12-15 | 2021-11-08 |
| Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714 Ocrelizumab - Multiple Sclerosis, Relapse | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 51 | 2018-11-11 | 2023-09-06 |
| Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells T-reg depleted DLI, Standard DLI - Hematological Malignancies, Regulatory T Cell Depletion | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 52 | 2018-02-22 | 2023-12-18 |
| MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT donor lymphocyte infusion - Minimal Residual Disease, Donor Lymphocyte Infusion | Phase 2 / Phase 3 | Completed | Nanfang Hospital, Southern Medical University | 206 | 2016-01-01 | 2020-02-25 |
| Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy Peginterferon alfa-2a, Ribavirin, Amantadine - Hepatitis C, Chronic, Relapse | Phase 3 | Unknown | University of Hamburg-Eppendorf | 300 | 2005-11-01 | 2007-03-09 |
Recurrence (7) · Hematologic Neoplasms (1) · Hepatitis C, Chronic (1) · Malaria, Vivax (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Chronic Progressive (1) · Neoplasm, Residual (1)
Disease Attributes (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Chronic Disease (2) · Infections (2) · Neoplasms (2) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Blood-Borne Infections (1) · Communicable Diseases (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Digestive System Diseases (1) · Flaviviridae Infections (1) · Hematologic Diseases (1)
Acetylcysteine (1) · Amantadine (1) · Antilymphocyte Serum (1) · Busulfan (1) · Cyclophosphamide (1) · Cyclosporine (1) · Cytarabine (1) · Decitabine (1) · Mycophenolic Acid (1) · Primaquine (1) · Ribavirin (1) · Semustine (1) · Sorafenib (1) · ocrelizumab (1) · peginterferon alfa-2a (1)
Assistance Publique - Hôpitaux de Paris (2) · Nanfang Hospital, Southern Medical University (2) · The First Affiliated Hospital of Soochow University (1) · University of California, San Francisco (1) · University of Hamburg-Eppendorf (1)
China (2) · France (2) · Germany (1)
Qifa Liu (2) · Bruno Stankoff, MD Ph.D (1) · Peter Buggisch, Dr. (1) · Yue Han, Prof. (1)